Details for New Drug Application (NDA): 214907
✉ Email this page to a colleague
NDA 214907 describes CYTALUX, which is a drug marketed by On Target Labs and is included in one NDA. It is available from one supplier. There are six patents protecting this drug. Additional details are available on the CYTALUX profile page.
The generic ingredient in CYTALUX is pafolacianine sodium. One supplier is listed for this compound. Additional details are available on the pafolacianine sodium profile page.
The generic ingredient in CYTALUX is pafolacianine sodium. One supplier is listed for this compound. Additional details are available on the pafolacianine sodium profile page.
Summary for 214907
| Tradename: | CYTALUX |
| Applicant: | On Target Labs |
| Ingredient: | pafolacianine sodium |
| Patents: | 6 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 214907
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 214907
| Mechanism of Action | Fluorescence Contrast Activity |
Suppliers and Packaging for NDA: 214907
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| CYTALUX | pafolacianine sodium | SOLUTION;INTRAVENOUS | 214907 | NDA | On Target Laboratories, Inc. | 81052-138 | 81052-138-10 | 10 CARTON in 1 CARTON (81052-138-10) / 1 VIAL, SINGLE-DOSE in 1 CARTON / 1.6 mL in 1 VIAL, SINGLE-DOSE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | EQ 3.2MG BASE/1.6ML (EQ 2MG BASE/ML) | ||||
| Approval Date: | Nov 29, 2021 | TE: | RLD: | Yes | |||||
| Regulatory Exclusivity Expiration: | Dec 16, 2025 | ||||||||
| Regulatory Exclusivity Use: | ADJUNCT FOR INTRAOPERATIVE IDENTIFICATION OF MALIGNANT AND NONMALIGNANT PULMONARY LESIONS IN ADULT PATIENTS WITH KNOWN OR SUSPECTED CANCER IN THE LUNG | ||||||||
| Regulatory Exclusivity Expiration: | Nov 29, 2028 | ||||||||
| Regulatory Exclusivity Use: | AS AN ADJUNCT FOR INTRAOPERATIVE IDENTIFICATION OF MALIGNANT LESIONS IN ADULT PATIENTS WITH OVARIAN CANCER | ||||||||
| Regulatory Exclusivity Expiration: | Nov 29, 2026 | ||||||||
| Regulatory Exclusivity Use: | NEW CHEMICAL ENTITY | ||||||||
Complete Access Available with Subscription
